West Pharmaceutical and Others Set for Ex-Dividend Trading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3d ago
0mins
Source: NASDAQ.COM
- West Pharmaceutical Ex-Dividend: West Pharmaceutical Services, Inc. (WST) will trade ex-dividend on January 28, 2026, with a quarterly dividend of $0.22, leading to an expected price drop of approximately 0.09%, indicating a stable dividend payment history.
- Heritage Financial Dividend Update: Heritage Financial Corp (HFWA) is set to pay a quarterly dividend of $0.24 on February 11, 2026, with an anticipated price drop of about 0.90%, reflecting a relatively high annual yield of 3.61%.
- Entegris Dividend Details: Entegris Inc (ENTG) will pay a quarterly dividend of $0.10 on February 18, 2026, with an expected price decline of around 0.09%, showing a stable annual yield of 0.35%.
- Market Performance Overview: On Monday, shares of West Pharmaceutical, Heritage Financial, and Entegris fell by approximately 4.5%, 5.5%, and 3.2%, respectively, indicating market reactions to the upcoming ex-dividend dates.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on WST
Wall Street analysts forecast WST stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WST is 348.70 USD with a low forecast of 285.00 USD and a high forecast of 375.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 235.890
Low
285.00
Averages
348.70
High
375.00
Current: 235.890
Low
285.00
Averages
348.70
High
375.00
About WST
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates in two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers elastomers & primary containment, drug delivery devices, integrated solutions, and analytical lab services, primarily to biologic, generic, and pharmaceutical drug customers. The Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
West Pharmaceutical Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services will announce its Q4 and full-year 2025 financial results before the market opens on February 12, 2026, which is expected to impact investor confidence.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 8:00 a.m. Eastern Time to discuss the financial results and business expectations, offering participants the option to register in advance for questions.
- Investor Resources: A slide presentation will be made available on the company's website in the Investors section on the day of the call, ensuring that investors can access key information to make informed decisions.
- Company Background: West Pharmaceutical Services generated $2.89 billion in net sales in fiscal year 2024, and as a leading provider of injectable drug solutions, supports customers in delivering over 41 billion components and devices annually.
Continue Reading
West Pharmaceutical Services to Release Q4 and Full-Year 2025 Financial Results
- Earnings Release Schedule: West Pharmaceutical Services will announce its Q4 and full-year 2025 financial results before the market opens on February 12, 2026, which is expected to significantly impact investor sentiment.
- Conference Call Details: Following the earnings release, the company will hold a conference call at 8:00 a.m. Eastern Time to discuss the financial results and business expectations, with advance registration required for participants to ask questions.
- Investor Resources: A slide presentation will be made available on the day of the call in the Investors section of the company's website, ensuring that investors have access to critical information to support their decision-making.
- Company Overview: In fiscal year 2024, West generated $2.89 billion in net sales, positioning itself as a leading provider of innovative injectable solutions, delivering over 41 billion components and devices annually, which underscores its strong market presence.
Continue Reading